DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,584,137 | +5.1% | 66,845 | +1.6% | 4.71% | +5.2% |
| Q2 2023 | $15,786,136 | +20.4% | 65,776 | +26.5% | 4.48% | +19.0% |
| Q1 2023 | $13,106,223 | +82401.7% | 52,001 | -15.5% | 3.76% | -25.9% |
| Q4 2022 | $15,886 | -99.9% | 61,505 | 0.0% | 5.08% | 0.0% |
| Q3 2022 | $15,886,000 | +3.8% | 61,505 | +1.9% | 5.08% | +6.5% |
| Q2 2022 | $15,299,000 | -12.0% | 60,345 | +1.8% | 4.77% | +5.5% |
| Q1 2022 | $17,390,000 | +2.9% | 59,284 | +15.4% | 4.52% | +10.5% |
| Q4 2021 | $16,895,000 | +13.2% | 51,352 | +4.7% | 4.09% | -0.5% |
| Q3 2021 | $14,926,000 | +12.5% | 49,027 | -0.8% | 4.11% | +9.4% |
| Q2 2021 | $13,268,000 | +16.9% | 49,443 | -2.0% | 3.76% | +2.3% |
| Q1 2021 | $11,352,000 | -6.5% | 50,433 | -7.7% | 3.68% | -10.9% |
| Q4 2020 | $12,144,000 | +2.4% | 54,669 | -0.8% | 4.13% | -8.6% |
| Q3 2020 | $11,865,000 | +16.0% | 55,102 | -4.7% | 4.52% | +2.7% |
| Q2 2020 | $10,226,000 | +29.1% | 57,827 | +1.1% | 4.40% | -2.0% |
| Q1 2020 | $7,918,000 | -13.3% | 57,205 | -3.8% | 4.48% | -1.2% |
| Q4 2019 | $9,130,000 | +5.6% | 59,486 | -0.6% | 4.54% | -6.0% |
| Q3 2019 | $8,646,000 | -0.8% | 59,862 | -1.9% | 4.83% | -4.4% |
| Q2 2019 | $8,719,000 | -43.4% | 61,004 | -47.7% | 5.05% | +2.6% |
| Q1 2019 | $15,395,000 | +151.9% | 116,615 | +96.7% | 4.93% | +11.7% |
| Q4 2018 | $6,112,000 | -3.2% | 59,271 | +2.0% | 4.41% | +11.8% |
| Q3 2018 | $6,316,000 | +8.4% | 58,122 | -1.6% | 3.94% | +2.3% |
| Q2 2018 | $5,826,000 | +0.1% | 59,042 | -0.7% | 3.86% | -2.2% |
| Q1 2018 | $5,821,000 | +0.2% | 59,456 | -5.0% | 3.94% | +0.4% |
| Q4 2017 | $5,812,000 | +8.4% | 62,612 | +0.2% | 3.93% | +10.0% |
| Q3 2017 | $5,360,000 | +10.1% | 62,481 | +8.3% | 3.57% | +8.5% |
| Q2 2017 | $4,867,000 | +1.5% | 57,672 | +2.9% | 3.29% | -1.4% |
| Q1 2017 | $4,795,000 | +11.1% | 56,061 | +1.1% | 3.34% | -1.6% |
| Q4 2016 | $4,316,000 | +0.3% | 55,444 | +1.0% | 3.39% | -1.4% |
| Q3 2016 | $4,301,000 | – | 54,869 | – | 3.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |